Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

Roivant Sciences Ltd.'s Vant model offers risk-isolated growth and monetization flexibility. Click for key ROIV drivers ...

After years of unexplained pain in her joints, nerves, and stomach, this writer finally found some relief—and a new community ...

Detailed price information for Dianthus Therapeutics Inc (DNTH-Q) from The Globe and Mail including charting and trades.

Key Points GAAP EPS loss was $(0.88) for Q2 2025 GAAP revenue was $0.2 million for Q2 2025 Research and development expenses increased by 45.3%, while general and administrative expenses rose by 48.3% ...

Among patients with T2D and DPN, some with nonpainful DPN developed neuropathic pain over a 5-year period while others with painful DPN experienced relief.

While some patients with nonpainful diabetic polyneuropathy (DPN) developed neuropathic pain over a 5-year period, a significant percentage with painful DPN at baseline had reduced pain over the same ...

Background: Polyneuropathy with IgM monoclonal gammopathy can be a disabling disorder necessitating treatment. Methods: In a prospective open label trial, 17 patients with disabling IgM MGUS ...